02:28:16 EDT Thu 23 Sep 2021
Enter Symbol
or Name

Login ID:
Khiron Life Sciences Corp
Symbol KHRN
Shares Issued 150,717,068
Close 2021-03-22 C$ 0.71
Recent Sedar Documents

Khiron delivers medical cannabis to Germany

2021-03-22 09:41 ET - News Release

Mr. Tejinder Virk reports


Khiron Life Sciences Corp. has successfully delivered EU-GMP (European Union good manufacturing practices) medical cannabis product to Germany. In collaboration with Nimbus Health, a leading medical cannabis distributor in Germany, Khiron is now positioned for imminent first sales in Germany. Khiron products are currently in inventory in the Nimbus warehouse, ready to be prescribed to patients and distributed through a vast network of 300 pharmacies across Germany.

This major milestone represents a new revenue stream for the company and positions Khiron's European team to execute on its German medical strategy. Leveraging its partner's large distribution network and Khiron's continuing investments in physician education, the company has secured immediate access to the German market. Khiron 1/14 will focus on indications such as anxiety, substance-use disorder and migraines, addressing patient needs and improving access to medical cannabis.

Tejinder Virk, president of Khiron Europe, commented: "Since signing our distribution agreement with Nimbus Health in 2020, the company's European sales and marketing teams have been actively educating doctors and raising awareness for our products. We are excited to launch our portfolio with Khiron 1/14, a product that covers unmet medical need in the German market. As we continue to expand our presence in the U.K. and Germany, we will leverage our clinical expertise from Colombia to provide the EU market with additional cannabis-based medicinal products."

Franziska Katterbach, managing director and chief legal officer for Khiron Europe based in Frankfurt, commented: "I would like to thank our European team for their unwavering perseverance over the past few months; their efforts have allowed us to achieve this significant milestone despite the challenges of the global pandemic and Germany's strict regulatory environment. With all permits in place and product now available for sale, we look forward to increasing our presence in this growing market with over 60,000 medical cannabis patients and a population of over 82 million people. We are already developing additional cannabis-based medicinal products from our certified strains recently imported from Colombia to improve access and product selection for German patients."

Through its EU-GMP certified supply chain partners in Europe, Khiron continues to expand its offering of world-class medical cannabis products, targeting the introduction of cannabis-based medicinal products based on those already distributed by the company in Colombia and Peru. With Khiron's proof of concept now validated in Colombia, the company plans to leverage its clinical data and intellectual property, educational platforms, and technology and systems to expand into new markets.

About Khiron Life Sciences Corp.

Khiron is a vertically integrated medical and CPG (consumer packaged goods) cannabis company with core operations in Latin America and operational activity in Europe and North America. Khiron is the leading medical cannabis provider in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low-tetrahydrocannabinol and high-tetrahydrocannabinol medical cannabis products. The company has filled medical cannabis prescriptions in Colombia, Peru and the United Kingdom, and it is positioned to commence sales of medical cannabis in Germany and Brazil in early 2021.

Leveraging wholly owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation and agricultural infrastructure to drive prescriptions and brand loyalty. Its well-being unit launched the first branded CBD (cannabidiol) skin care brand in Colombia, with Kuida now marketed in multiple jurisdictions in Latin America, the United States and the United Kingdom. The company is led by co-founder and chief executive officer, Alvaro Torres, together with an experienced and diverse executive team and board of directors.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.